{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:35:17Z","timestamp":1787315717091,"version":"build-2736575974"},"publisher-location":"Chichester, UK","reference-count":27,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004311.pub2","type":"reference-entry","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T23:08:27Z","timestamp":1137712107000},"source":"Crossref","is-referenced-by-count":66,"title":["Opioids for the management of breakthrough (episodic) pain in cancer patients"],"prefix":"10.1002","author":[{"given":"Giovambattista","family":"Zeppetella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria DC","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD004311.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.1998.16.10.3238","article-title":"Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain","volume":"16","author":"Christie","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004311.pub2-BIB2|cit2","first-page":"26","article-title":"Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)","volume":"3","author":"Coluzzi","year":"2002","journal-title":"Douleurs"},{"issue":"1-2","key":"10.1002\/14651858.CD004311.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3959(00)00427-9","article-title":"Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)","volume":"91","author":"Coluzzi","year":"2001","journal-title":"Pain"},{"issue":"8","key":"10.1002\/14651858.CD004311.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jnci\/90.8.611","article-title":"Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients","volume":"90","author":"Farrar","year":"1998","journal-title":"Journal of the National Cancer Institute"},{"issue":"2-3","key":"10.1002\/14651858.CD004311.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0304-3959(98)00179-1","article-title":"Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study","volume":"79","author":"Portenoy","year":"1999","journal-title":"Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB6|cit6","series-title":"Proceedings of the American Society of Clinical Oncology","first-page":"52a","article-title":"Double blind, randomized study of the treatment of breakthrough pain in cancer patients: oral transmucosal fentanyl citrate versus placebo (Meeting abstract)","author":"Cleary","year":"1997"},{"key":"10.1002\/14651858.CD004311.pub2-BIB7|cit7","series-title":"Proceedings of the American Society of Clinical Oncology","first-page":"52a","article-title":"A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients (Meeting abstract)","author":"Coluzzi","year":"1997"},{"issue":"3","key":"10.1002\/14651858.CD004311.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(87)90042-X","article-title":"Buprenorphine vs. morphine via the epidural route: a controlled clinical study of respiratory effects and analgesic activity","volume":"29","author":"Pasqualucci","year":"1987","journal-title":"Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00520-004-0595-4","article-title":"Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis","volume":"12","author":"Shaiova","year":"2004","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD004311.pub2-BIB10|cit10","series-title":"Proceedings of the American Society of Clinical Oncology","first-page":"52a","article-title":"Oral transmucosal fentanyl citrate produces pain relief faster than medication typically used for breakthrough pain in cancer patients (Meeting abstract)","author":"Simmonds","year":"1997"},{"key":"10.1002\/14651858.CD004311.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0885-3924(95)00052-Z","article-title":"A prospective multi-center assessment of the Edmonton staging system for cancer pain","volume":"10","author":"Bruera","year":"1995","journal-title":"Journal of Pain Symptom Management"},{"key":"10.1002\/14651858.CD004311.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0304-3959(99)00073-1","article-title":"An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain","volume":"82","author":"Caraceni","year":"1999","journal-title":"Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrar","year":"2000","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD004311.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0885-3924(03)00162-3","article-title":"Clinically important changes in acute pain outcome measures: a validation study","volume":"25","author":"Farrar","year":"2003","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD004311.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1054\/jpai.2002.27136","article-title":"A survey of pain-related hospitalisations, emergency department visits, and physicians office visits reported by cancer patients with and without history of breakthrough pain","volume":"3","author":"Fortner","year":"2002","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","article-title":"Morphine and alternative opioids in cancer pain: the EAPC recommendations","volume":"84","author":"Hanks","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004311.pub2-BIB17|cit17","first-page":"6","article-title":"Oral transmucosal fentanyl citrate for the management of breakthrough pain","volume":"8","author":"Hanks","year":"2001","journal-title":"European Journal of Palliative Care"},{"key":"10.1002\/14651858.CD004311.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0304-3959(02)00293-2","article-title":"Cancer breakthrough pain characteristics and responses to treatment at a VA medical centre","volume":"101","author":"Hwang","year":"2003","journal-title":"Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports on randomised clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD004311.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1213\/00000539-199909000-00038","article-title":"The Relative Potency of Oral Transmucosal Fentanyl Citrate Compared with Intravenous Morphine in the Treatment of Moderate to Severe Postoperative Pain","volume":"89","author":"Lichtor","year":"1999","journal-title":"Anesthesia and Analgesia"},{"issue":"5","key":"10.1002\/14651858.CD004311.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0885-3924(03)00099-X","article-title":"Clinically important changes - what's important and whose change is it anyway?","volume":"25","author":"McQuay","year":"2003","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD004311.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.10249","article-title":"Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care","volume":"94","author":"Mercadante","year":"2002","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD004311.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","article-title":"Breakthrough pain: definition, prevalence and characteristics","volume":"41","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB24|cit24","first-page":"S16","article-title":"Treatment of temporal variations in chronic cancer pain","volume":"24","author":"Portenoy","year":"1997","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD004311.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","article-title":"Breakthrough pain: characteristics and impact in patients with cancer pain","volume":"81","author":"Portenoy","year":"1999","journal-title":"Pain"},{"key":"10.1002\/14651858.CD004311.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.1988.46","article-title":"Rescue factor: a design for evaluating long-acting analgesics","volume":"43","author":"Savarese","year":"1988","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD004311.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.4.4.493","article-title":"The pharmacotherapy of cancer-related episodic pain","volume":"4","author":"Zeppetella","year":"2003","journal-title":"Expert Opinion in Pharmacotherapy"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004311.pub4","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"record-id":"31941"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004311.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T03:03:03Z","timestamp":1683342183000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004311.pub2"}},"subtitle":[],"editor":[{"given":"Giovambattista","family":"Zeppetella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,1,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004311.pub2","relation":{},"subject":[],"published":{"date-parts":[[2006,1,25]]}}}